Penumbra (NYSE:PEN) announced additional results from its STORM-PE trial of computer-assisted vacuum thrombectomy (CAVT).

Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest ...

NEW YORK - Penumbra, Inc. (NYSE:PEN), a $9.87 billion medical technology company with strong financial health and ~13% revenue growth over the last twelve months, announced Monday that its computer ...

Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum ...

Penumbra, Inc. PEN recently received FDA clearance for the RED 62 Reperfusion Catheter. Following this regulatory go-ahead, the company has also initiated commercial availability of the catheter ...

BOSTON--(BUSINESS WIRE)--Penumbra, Inc. (NYSE:PEN), a global interventional therapies company, today announced U.S. commercial availability of its most advanced thrombectomy device, the ACE™68 ...

Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot ...

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly ...

The medical device specialist completed enrollment for a clinical trial of its latest thrombectomy product. This addresses a significant medical challenge at a time when the U.S. population is aging.